ERNEST HAWK to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications ERNEST HAWK has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.042
-
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
Score: 0.012
-
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
Score: 0.011
-
Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:79-85.
Score: 0.007
-
Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl. 1996; 25:1-14.
Score: 0.007
-
Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl. 1995; 23:1-9.
Score: 0.006